Adverse Drug Event Prevention Using Structured Pharmacist Review

Status Completed

Clinical Trial Summary

The next four decades will see a marked expansion of the elderly population in Ireland, in particular people aged over 80 yrs. Persons aged over 80 are the highest consumers of prescription medicines in Ireland and have the highest prevalence rates of major polypharmacy. Polypharmacy is intimately linked with serious adverse drug events (ADEs) and consequent major morbidity and mortality. Epidemiological data from the Unites States indicate that ADEs is the fifth most common cause of death nationally. Experts suggest that effective evidence based interventions can be applied to this major public health problem.

A recently described approach to hospitalised older patients' medication optimisation is that of Spinewine and colleagues at Louvain University, Belgium. In this model, a pharmacist with expertise in geriatric pharmacotherapy routinely reviews the prescriptions of older patients from admission to discharge. The pharmacist provides a detailed pharmaceutical care plan for older patients and their carers where appropriate as well as feedback information to prescribers in the event of detecting instances of probable medication inappropriateness. Whenever an opportunity for medication optimisation is identified, the pharmacist discusses the opportunity with the prescriber who can accept or reject the intervention. At discharge from hospital, the pharmacist also provides written and verbal information on treatment changes to the patient / caregiver and GP. The intervention therefore represents a comprehensive pharmaceutical care approach that is based upon careful review and subsequent consensus on individualised pharmacotherapy. In an RCT comparison of this approach with standard care, older patients in the intervention arm of the study had significant improvements in medication appropriateness (medication appropriateness index (MAI), Beers' criteria, and Assessing Care of Vulnerable Elders (ACOVE) criteria.). Expert pharmacist review of older peoples' medication in hospital is a proven intervention in term of reducing inappropriateness of medication.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention

Related Conditions & MeSH terms

Adverse Drug Reactions
Drug-Related Side Effects and Adverse Reactions

Clinical Trial Details

NCT number	NCT01467128
Study type	Interventional
Source	University College Cork
Contact
Status	Completed
Phase	Phase 4
Start date	June 2011
Completion date	June 2012

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02239237` - Post-marketing Safety Surveillance of Compound Kuh-seng Injection: a Registry Study
Completed	`NCT02191358` - YouScript IMPACT Registry	N/A
Recruiting	`NCT04743544` - Influence of CYP2C19 Genotype on Safety and Efficacy of Voriconazole in Pediatric Patients With Hematologic Malignancy
Recruiting	`NCT04547335` - The Influence of CYP2C19 Polymorphisms on the Safety and Efficacy of Voriconazole
Completed	`NCT02378220` - Pharmacogenetic Testing Among Home Health Patients	N/A
Completed	`NCT01354730` - A Pharmacovigilance Study for AdimFlu-S (A/H1N1) Influenza Vaccine in Pregnant Women	Phase 4
Recruiting	`NCT04496024` - Ofloxacin Concentration-toxicity Relationship in the Elderly	N/A
Completed	`NCT02097654` - Clinical Trial of a New Software ENgine for the Assessment & Optimization of Drug and Non-drug Therapy in Older peRsons	N/A
Completed	`NCT01764204` - Hospital Intensive Monitoring of Adverse Drug Reactions of Qingkailing Injection In The Next Two Years	N/A
Completed	`NCT04252326` - The Knowledge, Attitudes and Practices of Healthcare Workers on Drug Hypersensitivity Reactions in Children	N/A
Completed	`NCT04279470` - Chimeric Antigen Receptor T-cell and Cellular Therapies for the Treatment of cAncer or BLood Diseases: Evaluation of Reporting of Adverse Events
Recruiting	`NCT03640884` - Post-marketing Safety Surveillance of Xueshuantong-Injection : a Registry Study
Completed	`NCT02122965` - The Effect of Medication Review in High-risk Emergency Department Patients	N/A
Active, not recruiting	`NCT06456086` - Effect of Epstein-Barr Virus on Macrophage M2/M1 Migration and EphA2 Expression in Adverse Drug Reactions
Completed	`NCT01058122` - Collection, Evaluation and Assessment of Adverse Drug Reactions on the Oncology Ward
Recruiting	`NCT04479553` - Post-marketing Safety Surveillance of Qizhi Tongluo Capsules:a Registry Study.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.